Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TEMSIROLIMUS for Prostate cancer: Side Effects & Safety Data

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

There are 11 adverse event reports in the FDA FAERS database where TEMSIROLIMUS was used for Prostate cancer.

Most Reported Side Effects for TEMSIROLIMUS

Side Effect Reports % Deaths Hosp.
Disease progression 158 9.6% 66 50
Death 136 8.3% 135 14
Stomatitis 100 6.1% 17 51
Anaemia 89 5.4% 16 44
Neoplasm progression 84 5.1% 33 24
Vomiting 81 4.9% 13 52
Diarrhoea 79 4.8% 9 51
Febrile neutropenia 78 4.7% 1 66
Pneumonia 76 4.6% 23 52
Off label use 75 4.6% 15 12
Fatigue 74 4.5% 15 25
Pyrexia 73 4.4% 11 52
Dehydration 69 4.2% 4 62
Thrombocytopenia 62 3.8% 15 21
Dyspnoea 59 3.6% 16 27

Other Indications for TEMSIROLIMUS

Renal cell carcinoma (213) Metastatic renal cell carcinoma (131) Embryonal rhabdomyosarcoma (121) Product used for unknown indication (88) Renal cancer (69) Mantle cell lymphoma (65) Neoplasm malignant (60) Rhabdomyosarcoma (51) Alveolar rhabdomyosarcoma (38) Metastatic malignant melanoma (35)

Other Drugs Used for Prostate cancer

LEUPROLIDE (45,399) ENZALUTAMIDE (25,954) RELUGOLIX (18,752) ABIRATERONE (12,209) APALUTAMIDE (3,286) GOSERELIN (2,080) DEGARELIX (2,035) BICALUTAMIDE (1,832) SIPULEUCEL-T (1,720) DENOSUMAB (1,627)

Related Pages

TEMSIROLIMUS Full Profile All Prostate cancer Drugs TEMSIROLIMUS Demographics TEMSIROLIMUS Timeline